BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Infographics: Dynamic digital data analysis
Special reports
Aging
Alzheimer's disease
Artificial intelligence
Biosimilars
China CAR T
Coronavirus
Infographics: Dynamic digital data analysis
Israel
IVDs on the rise
Radiopharmaceuticals
Rise of obesity
Top Biopharma Trends of 2023
Top Med-tech Trends of 2023
Top Preclinical Trends of 2023
Premium reports
BioWorld Financings Reports
Disease Incidence & Prevalence Summaries
BioWorld. Link to homepage.
sign in
Sign Out
My Account
Subscribe
BioWorld - Thursday, April 25, 2024
Home
»
Newsletters
» BioWorld Science
BioWorld Science
Feb. 11, 2020
View Archived Issues
Distinguishing real from backseat drivers
Read More
Blocking bad bone
Read More
Discovery of macrocyclic ASK1 inhibitors with potential applications in neurodegenerative diseases
Read More
SLC25A1 plays a role in the pathogenesis of fatty liver disease and is a druggable target
Read More
Arbutus discontinues development of its first generation oral HBV RNA-destabilizer
Read More
Myovant reports positive one-year data from phase III LIBERTY extension study
Read More
Rezolute initiates phase IIb study of RZ-358 in congenital hyperinsulinism
Read More
Promising preclinical data presented for AdC-gDE765dt vaccine
Read More
Taiho Pharmaceutical presents phase I data for TAS-0313 cancer peptide vaccine
Read More
Initial phase I data for binimetinib plus pembrolizumab in TNBC
Read More
First data presented for UV-1 cancer vaccine combined with ipilimumab in malignant melanoma
Read More
Newly identified HIV broadly neutralizing antibody is hard to escape
Read More
Intellia presents new results for its cell therapy development programs
Read More
Phenex Pharmaceuticals AG patents new AhR antagonists
Read More
BeiGene discloses adenosine A2A receptor antagonists
Read More
Sestrins protect against muscle wasting by coordinating anabolic and catabolic pathways
Read More
Merck KGaA presents PSMB8 inhibitors
Read More
Roche describes new oligonucleotides targeting Spi1 proto-oncogene
Read More
Intrexon patents ROR1-targeting CARs
Read More
Primary objective met in phase II study of TTP-399 in type 1 diabetes
Read More
Phase III trial of troriluzole in generalized anxiety disorder misses primary endpoint
Read More
FDA accepts IND for phase I/II study of Inovio's INO-3107 for recurrent respiratory papillomatosis
Read More
Health Canada clears Bold to begin phase Ib study of BOLD-100 in gastrointestinal cancers
Read More